Casdin Capital’s OptimizeRx OPRX Stock Holding History

Casdin Capital’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500,000	Closed	-$7.32M	–	42
2023 Q1	$7.32M	Buy	500,000 +240,000	+92%	+$4.02M	0.6%	32
2022 Q4	$4.37M	Buy	+260,000	New	+$4.5M	0.34%	37

Other funds holding OPRX

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Casdin Capital's OPRX Position: Q2 2023 in Review

Casdin Capital sold out of OptimizeRx (OPRX) in Q2 2023, closing a stake of 500,000 shares — an estimated $7.32M sold.

Casdin Capital first reported a position in OPRX in Q4 2022 and held it in 2 quarters. The position peaked at $7.32M in Q1 2023. 102 funds tracked by Wall St. Rank hold OPRX as of Q2 2023.

Casdin Capital reported no remaining OptimizeRx position as of Q2 2023 after selling out during the quarter.
Casdin Capital sold 500,000 OptimizeRx shares in Q2 2023, an estimated $7.32M.
Casdin Capital first reported a position in OptimizeRx in Q4 2022 and held it in 2 quarters.
Casdin Capital's OptimizeRx position peaked at $7.32M in Q1 2023.
102 funds tracked by Wall St. Rank held OptimizeRx as of Q2 2023.

Based on Casdin Capital's 13F filing for Q2 2023, filed 14 Aug 2023.